The medical market can learn a thing from the consumer electronics marketing: reaping the benefits from open platform technologies. Ronald Dekker, senior research scientist at Philips Research, will talk about this subject during his keynote at the Nano4Health track, part of the virtual MicroNanoConference 2020.

By: Dimitri Reijerman, FHI

Dekker, who also works at the Delft University of Technology, has a lot of experience from the development of IC technology, but nowadays his focus is on the integration of complex electronic sensor functionality on the tip of smart catheters at Philips. But during his work, he discovered the problems many medical companies, especially smaller ones, have with bringing high tech products to the market. “I noticed, also in my work at the university, there’s a lot of research going on in smart devices”, Dekker says. “But in the end only a fraction of them reaches the marketplace. We also have this experience at Philips where we’re working on the technology for smart catheters.”

He was intrigued and started to zoom in on this problem: “We started looking at the causes of this issue. Many people may say it’s complicated regulations or the validation processes. But we think the awareness within the medical domain about the concept and benefits of platform technologies is just not there. So everyone is making their own stand-alone product. When we looked at the market for catheters at Philips, we discovered that for every single catheter product a new piece of technology has been developed. This development process is very expensive, nanotechnology in particular. In many cases it takes universities several years and requires tens of millions of euros, while in many domains these investments are just too large to earn them back.”

Especially start-ups have a tough time. Dekker sees this at his labs: “We at Philips have a medical certified clean room. Customers visit our labs, for example with a chip to test for cell sorting and microfluidica. When we made an assessment of these customers, we noticed all forty of them developed their own technology. But these start-ups don’t have the money to bring the final product on the market, so sadly their ideas fail somewhere in the process. This is one of the main reasons why the market for organ-on-a-chip products for example is developing so slowly.”

To solve these issues, medical companies need to look at consumer electronics, Dekker believes: “The market for consumer electronics has solved this problem many years ago by using mostly open platform technologies. When I started working at Philips at the semiconductor department, we initially did all the work ourselves. We produced our own silicon wafers and had our own assembly lines. But we stopped first with making these silicon wafers, because the whole industry realized: this is not a key technology but a platform technology. So only a few specialized companies started making these wafers. Next where photomasks. Nowadays someone with a good workstation and a design kit can start a sole proprietorship in semiconductor technology.”

Dekker and a few colleagues started working on this challenges. “We think it’s possible to develop some platform technologies within the medical domain”, he says. “These platform technologies could be used by multiple users for multiple applications, so it will become possible to create the volumes and revenues needed for sustainable innovation in the future.”

ECSEL program

The ECSEL Joint Undertaking program, an element of the EU’s Horizon 2020 innovation programs, wants to help innovative companies. The ECSEL comity described a few so called ‘light houses’, themes so important you can’t catch them within one project. One of them is health. “Within this lighthouse we are telling the ECS industry about the emerging opportunities in the medical domain. We also want to enlighten the producers of medical devices about the benefits of platform technology, because value is shifting from core technologies to applications, AI, software and solutions. And thirdly: we are developing a community to bring projects together.”

As a derivative of ECSEL, last June the project Moore4Medical was launched. It aims at developing platforms for six emerging domains. “Especially these domains, which are very promising need platform technologies”, Dekker says. “We are already for example developing a smart microwell plate. These plates can contain chips from multiple manufacturers. That’s progress.”

In the end, collaboration is crucial, Dekker thinks: “If European medical companies can work together and develop these new technology platforms, I think they will have an advantage to companies from outside the European Union. And in some fields I see some movement. Within microfluidica there are some foundries who start to offer technologies as a platform. And looking into the future: photonics is a highly interesting technology for medical companies.”

If you want to visit the keynote of Ronald Dekker, please register at the website of the MicroNanoConference 2020.

This vision (nanovision 2030) is a multi-year plan for the knowledge and innovation agenda around the key enabling technology, nanotechnology. The foundation is the selective continuation of thenational FES programme NanoNextNL, supplemented by the input of a wide range of stakeholders. The initiators are the NanoNextNl and MinacNed foundations, an industry organisation within FHI. This encompasses the entire chain secured, from science – spinoff – startup –SME’s – large companies – end user.

Nanovision 2030 is a clear indicator of the position and application that nanotechnology occupies as a key enabling technology for solving societal challenges. This aligns with the four themes the Netherlands has chosen, health and healthcare, energy and sustainability, agriculture, water, and food, and security, and in line with the European Green deal. The programme outlined here, Nano4society, can make vital contributions to these mission-driven innovations. It combines excellent technology development with a dedicated governance system to safeguard that its outcomes will contribute to solving societal issues.

As illustration of the dynamics and flexibility/agility of the nanotech community, a special section on nano-solutions for the “Coronachallenge” is added.
Text by Prof. dr. ir. Albert van den Berg (UT) CHAIR

Direct download

Download the NanoVision 2030 (English version), includes COVID-19 research themes (PDF)


On December 16, 2019 the manifest was presented to Marc Hendrikse, ‘boegbeeld’ High Tech Systems and Materials (HTSM), by Dave Blank, Albert van den Berg and Ronny van ‘t Oever. Read the full article in Dutch here.




Wij werken er hard aan om in 2022 weer terug te komen met het Health Valley Event op locatie (én online)! Reserveer alvast de dagen (15,) 16 en 17 maart 2022 in je agenda. Zodra we updates hebben over ons (hybride) zorginnovatiecongres, dan maken we die natuurlijk bekend!

Het Health Valley Event is hét jaarlijkse hoogtepunt van Health Valley en dé plek waar je kunt zien en beleven hoe de nieuwste innovaties op het gebied van gezondheid en zorg in Nederland worden ontwikkeld en geïmplementeerd. Nationale en internationale bezoekers leggen hier nieuwe verbindingen. Bovendien laten zij zich inspireren door nieuwe trends en ontwikkelingen in en buiten de regio.

Pathé Nijmegen, Willem van Arenbergstraat 4, 6515 AT Nijmegen
Tickets € 99 tot € 349,- Eur.

November 4 
16:30-18:00 hrs (GMT+1 Amsterdam)

We have invited 2 keynote speakers for this Nano4Health session. Dr. Wim van Hoeve, CEO at Solstice Pharmaceuticals. He will discuss how Solstice uses microfluidics to produce a microbubble agent at point of care. He is joined by Dr. Max Sonnleitner CEO and founder of GENSPEED Biotech. Following these talks, Herman Blok, from Micronit Microtechnologies will invite you to a discussion in a Q&A.

The program is set up with 2 keynote talks followed by a Q&A session where you can ask your questions direct. You can also send in your questions in advance via email to Aurélie Veltema at